Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286098 | 1.00 | PTGS2 (0.41) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL1285734 | 0.86 | ALOX5 (0.44) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL1285733 | 0.86 | ALOX5 (0.44) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL633489 | 0.77 | PTGS1 (0.48) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL1286363 | 0.76 | PTGS1 (0.45) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL1285770 | 0.75 | NLRP3 (0.36) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL1285772 | 0.75 | NLRP3 (0.36) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL5795281 | 0.75 | PTGS1 (0.50) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL5795283 | 0.75 | PTGS1 (0.50) | PTGS2PTGS1CYP1A2CYP3A4TSHR | |
| SCHEMBL5795280 | 0.75 | PTGS1 (0.50) | PTGS2PTGS1CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791155-B2 | Chroman derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8044097-B2 | Chroman derivatives | AMPERE LIFE SCIENCES, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090192179-A1 | CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7514461-B2 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | EDISON PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2005033092-A1 | CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088783-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | PTGS2 236/4885PTGS1 214/4885CYP1A2 111/4885 |
| US-20090192179-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | PTGS2 236/4885PTGS1 214/4885CYP1A2 111/4885 |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | ALOX12, ALOX15, ALOX15B | PTGS2 435/4885PTGS1 296/4885CYP1A2 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.